Core Viewpoint - Financial Institutions, Inc. is set to release its first-quarter financial results for 2026 on April 23, 2026, after market close [1] Group 1: Earnings Release Information - The earnings conference call will take place on April 24, 2026, at 8:30 a.m. Eastern Time, hosted by the President and CEO, Martin K. Birmingham, and CFO, W. Jack Plants II [2] - Participants in the U.S. can join the call by dialing 1-833-461-5787 and using meeting ID 208517337, with a live webcast available on the company's website [2] Group 2: Company Overview - Financial Institutions, Inc. is a financial holding company with approximately $6.3 billion in assets as of December 31, 2025 [3] - The company offers banking and wealth management products and services through its subsidiary, Five Star Bank, which serves individuals, municipalities, and businesses in Western and Central New York [3] - Courier Capital, LLC, another subsidiary, provides customized investment management, financial planning, and consulting services to a diverse clientele including individuals, families, businesses, institutions, non-profits, and retirement plans [3]

Core Insights - Lexeo Therapeutics is advancing its cardiac pipeline, particularly LX2006 and LX2020, with significant progress reported in clinical trials and regulatory engagements [2][3]. Program Updates and Recent Progress - The SUNRISE-FA 2 pivotal trial protocol for LX2006 has been submitted to the FDA, with study initiation expected in the first half of 2026 [1][3]. - Positive interim clinical data for LX2006 show improvements in cardiac structure and function, including reduced left ventricular mass index (LVMI) and better modified Friedreich Ataxia Rating Scale (mFARS) scores [3][7]. - FDA has approved the comparability report for LX2006's manufacturing processes, allowing the use of the optimized process for the pivotal study [3]. - The company has established a research collaboration with Johnson & Johnson to explore targeted cardiac delivery of AAV gene therapy [1][7]. Financial Results - As of December 31, 2025, Lexeo reported cash, cash equivalents, and investments totaling $246.6 million, expected to fund operations into 2028 [1][14]. - Research and Development expenses decreased to $16.2 million for Q4 2025 from $18.4 million in Q4 2024, and for the full year, they were $63.8 million compared to $74.1 million in 2024 [6][12]. - General and Administrative expenses for Q4 2025 were $6.9 million, down from $9.0 million in Q4 2024, while for the full year, they increased to $45.5 million from $31.7 million [6][12]. - The net loss for Q4 2025 was $20.9 million, or $0.27 per share, compared to a net loss of $25.9 million, or $0.78 per share, in Q4 2024 [6][8]. Leadership and Strategic Initiatives - The leadership team has been strengthened with the appointment of a new Chief Medical Officer and other senior roles to enhance expertise in cardiac medicine [1][7]. - The company executed a $154 million equity financing in October 2025 to support the development of its cardiac pipeline and registrational readiness activities for LX2006 [7].

Core Insights - Sight Sciences, Inc. is an eyecare technology company focused on developing innovative interventional technologies to transform care and improve patients' lives [1][3] - The company will present at the 25th Annual Needham Healthcare Conference on April 13, 2026, at 11:15 am PT / 2:15 pm ET, with a live and archived webcast available [2] Company Overview - Sight Sciences specializes in minimally invasive or non-invasive solutions targeting prevalent eye diseases, aiming to enhance patient care and replace outdated treatment methods [3] - The company's key products include the OMNI® Surgical System and OMNI® Edge Surgical System, which are implant-free technologies for glaucoma surgery, indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma [3] - The OMNI Surgical System is CE Marked for specific procedures related to glaucoma treatment, while the SION® Surgical System is a bladeless device for excising trabecular meshwork [3] - The TearCare® System is 510(k) cleared in the U.S. for localized heat therapy in adult patients with evaporative dry eye disease, addressing meibomian gland disease [3]

Core Insights - The company has expanded its business to include a digital asset treasury (DAT) focused on acquiring and holding Solana tokens (SOL) [1][3] - Despite a downturn in the cryptocurrency industry due to geopolitical uncertainties, the company remains committed to its long-term SOL accumulation strategy [3] - The company aims to serve as an institutional access gateway for exposure to the Solana Ecosystem [3] Recent Business Updates - The DAT strategy has resulted in a strengthened balance sheet and sufficient liquidity for ongoing investments [3] - The company plans to generate incremental cash flows through initiatives like the Pacific Backbone project and a yield enhancement solution in collaboration with Kamino and Anchorage [3] - Strategic capital markets transactions will be pursued to achieve the company's objectives [3] Fourth Quarter 2025 Financial Results - Fourth quarter revenue was $5.2 million, a significant increase from $0.2 million in the prior-year period, primarily driven by $5.1 million in staking rewards [4] - Selling, general and administrative expenses rose to $13.0 million from $2.2 million in the prior-year period due to increased compensation costs and fees related to the DAT strategy [5] - Total operating expenses for the fourth quarter were $206.1 million, compared to $3.1 million in the prior-year period, largely due to non-cash charges for unrealized losses on digital assets [6] Full Year 2025 Financial Results - Full year revenue was $6.0 million, up from $0.5 million in the prior year, reflecting $5.5 million in staking rewards [10] - Total operating expenses for the full year were $249.4 million, compared to $13.8 million in the prior year, with a loss from operations of $243.8 million [12] - The net loss for the full year was $40.9 million, or a loss of $1.85 per share, compared to a net loss of $11.7 million in the prior year [13] Cash and Liquidity - As of December 31, 2025, the company had cash totaling $7.3 million and digital assets valued at $293.7 million, bringing the total to $301.0 million [14] - Common shares issued and outstanding totaled 43.7 million, with an additional 40.4 million shares from in-the-money warrants [14] Strategic Initiatives - The company launched the first-ever digital asset treasury to enable borrowing against natively staked SOL [7] - A strategic roadmap has been initiated to invest in a new low-latency cluster in Asia Pacific to enhance staking and validation [7]

Core Insights - Progress Software announced its financial results for the fiscal first quarter of 2026, ending February 28, 2026, highlighting its role as a provider of AI-powered digital experience and infrastructure software [1]. Financial Results - The earnings release and supplemental slide presentation are available on the Progress Investor Relations webpage, indicating transparency and accessibility of financial information [2]. Conference Call - A conference call is scheduled for today at 5:00 p.m. ET to discuss the results and future outlook, providing an opportunity for stakeholders to engage directly with company leadership [2][3]. Company Overview - Progress Software empowers organizations to achieve transformational success amidst disruptive changes, focusing on responsible AI-powered applications and personalized digital experiences [4]. - The company serves a wide range of businesses, providing the necessary products, expertise, and vision to leverage AI disruption as a competitive advantage [4].

Core Viewpoint - Beeline Holdings, Inc. is positioned for accelerated growth in the digital mortgage and fractional equity markets, with a focus on improving loan economics and achieving a $100 million run rate in the coming years [4][5]. Financial Performance - Net revenue for Q4 2025 reached $2.5 million, reflecting a 127% increase year-over-year and an 8.3% increase sequentially [5]. - The origination volume for Q4 2025 was $84.7 million, up 44% year-over-year [5]. - Operating expenses increased, primarily due to $4.2 million in non-cash stock-based compensation; excluding this, operating expenses rose by 19% alongside 127% revenue growth [5]. Operational Developments - The company ended 2025 with no corporate debt, significantly strengthening its balance sheet [5]. - Beeline launched the BeelineEquity platform, closing initial transactions recorded on the Blockchain in Q4 2025, with a growing pipeline entering 2026 [5]. - There was a 31% increase in average revenue per loan and an 18% decrease in average cost per loan, with positive trends continuing into January 2026 [5]. Management Insights - The CEO highlighted the company's strategic positioning at the intersection of digital mortgage origination, AI-driven financial infrastructure, and fractionalized real estate ownership [4]. - The management expressed confidence in the growth and margin trajectory, driven by improvements in originations, closings, and revenue per loan [4].

Company Announcement - Goosehead Insurance, Inc. has appointed Martin Thornthwaite as General Counsel and Corporate Secretary, effective March 30, 2026 [1] - John O'Connor will be departing Goosehead to pursue other opportunities [4] Martin Thornthwaite's Background - Mr. Thornthwaite previously served as Senior Vice President and Associate General Counsel at RealPage, Inc., overseeing complex commercial and consumer litigation, regulatory investigations, and employment-related legal matters [2] - He has experience in corporate governance and financial reporting processes, and has worked at Clark Hill PLC and Strasburger & Price LLP [2] - Mr. Thornthwaite holds a Juris Doctor from the SMU Dedman School of Law and a BBA in Finance and Business Honors from The University of Texas at Austin's McCombs School of Business [2] Leadership Perspective - Mark Miller, President and CEO of Goosehead, expressed confidence in Mr. Thornthwaite's legal expertise and experience in managing complex litigation and regulatory matters [3] - Mr. Thornthwaite expressed enthusiasm about supporting Goosehead's mission and contributing to the company's continued success [3] Company Overview - Goosehead is a rapidly growing independent personal lines insurance agency that distributes products and services through corporate and franchise locations across the United States [5] - The company represents over 200 insurance companies that underwrite personal and commercial lines, focusing on providing extraordinary value and a world-class service experience [5]

Core Insights - INmune Bio Inc. has transitioned from a mid-stage clinical company to a late-stage, registration-directed organization, focusing on harnessing the innate immune system to treat inflammatory diseases [4] - The company is preparing for significant regulatory submissions in 2026 and 2027, with two late-stage assets, CORDStrom™ and XPro™, expected to drive value for patients and shareholders [4] Financial Results - For the year ended December 31, 2025, the net loss attributable to common stockholders was approximately $45.9 million, compared to $42.1 million in 2024 [12] - Research and development expenses were approximately $20.7 million in 2025, down from $33.2 million in 2024, while general and administrative expenses increased to approximately $10.3 million from $9.5 million [12] - The company reported cash and cash equivalents of approximately $24.8 million as of December 31, 2025, an increase from $20.9 million in 2024 [17] CORDStrom™ Platform - CORDStrom™ is on track to file a Marketing Authorization Application (MAA) in the UK by mid-summer 2026, followed by anticipated submissions to the EMA and FDA [5] - The platform is designed to treat recessive dystrophic epidermolysis bullosa (RDEB) and has shown systemic disease-modifying capabilities in clinical trials [5][6] XPro™ Platform - XPro™ is advancing towards an adaptive Phase 2b/3 registrational pathway for early Alzheimer's Disease, with alignment achieved with the FDA [5] - The platform has reported zero cases of ARIA (Amyloid-related imaging abnormalities) across all clinical studies, distinguishing it from other therapies [8] Upcoming Events and Milestones - The company has scheduled a face-to-face meeting with the UK's MHRA in mid-May 2026 as part of its regulatory strategy [11] - INmune Bio's MINDFuL trial data was featured at the AD/PD 2026 conference, highlighting the importance of patient selection in clinical trials [5] Operational Readiness - The company has completed three commercial pilot-scale manufacturing runs at its Stevenage facility, ensuring readiness to supply the market upon regulatory approval [11] - INmune Bio estimates that its current cash position provides a runway through Q1 2027, supporting ongoing operations and clinical development [5]

Core Insights - The long-term efficacy and safety data from the ATTRibute-CM open-label extension trial demonstrate sustained clinical benefits of acoramidis in patients with ATTR-CM through Month 54, including significant reductions in all-cause and cardiovascular mortality [1][2][3] Efficacy and Safety Data - Acoramidis treatment resulted in a 44.7% reduction in all-cause mortality (ACM) and a 49.3% reduction in cardiovascular mortality (CVM) compared to placebo, marking the earliest timepoint in an open-label extension with such risk reduction [1][3] - The treatment mitigated the rise in NT-proBNP levels through Month 54, an effect not previously observed with disease-modifying treatments [1][3] - Continuous acoramidis treatment maintained heart failure-related quality of life scores (KCCQ-OS), indicating sustained improvements in both duration and quality of life for patients with ATTR-CM [1][3] Treatment Patterns and Patient Preferences - A real-world survey indicated that over half of physicians were not fully satisfied with current treatment options for ATTR-CM, and more than one-third of patients did not receive any treatment [4] - Patients expressed a preference for oral therapy, highlighting unmet treatment needs and the importance of shared decision-making in therapy selection [4] Regulatory Approvals - Acoramidis is approved as Attruby by the U.S. FDA and as BEYONTTRA by various European and Japanese regulatory agencies, with all labels specifying near-complete stabilization of TTR [4]

Core Insights - JCDecaux is supporting Céline Dion's return to the stage with a large-scale advertising campaign that began on March 23, 2026, culminating in an announcement from the Eiffel Tower on March 30, 2026 [1][3][5] Group 1: Campaign Overview - The campaign features iconic song titles displayed on JCDecaux's flagpole displays across Paris, creating a buzz and engaging the public without any images of the artist [2][5] - The campaign has generated significant online engagement, with over 300,000 reactions and comments on Instagram, indicating high anticipation for Dion's return [2][5] Group 2: Advertising Strategy - Starting March 31, the campaign will transition from teasers to full reveal, including official tour posters in major locations across Paris and other French cities [4][8] - Internationally, the campaign will utilize digital screens in major metropolitan areas, including New York, London, and Los Angeles, to amplify the announcement globally [8] Group 3: Company Positioning - JCDecaux reaffirms its role as a key partner for cultural events, showcasing the effectiveness of out-of-home media in creating memorable public experiences [5][6] - The company reported a revenue of €3,967.1 million in 2025 and operates 1,105,906 advertising panels worldwide, reaching a daily audience of 850 million people [9]